Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 204

1.

Inhibition of Ataxia-Telangiectasia Mutated and RAD3-related (ATR) overcomes oxaliplatin resistance and promotes anti-tumor immunity in colorectal cancer.

Combes E, Andrade AF, Tosi D, Michaud HA, Coquel F, Garambois V, Desigaud D, Jarlier M, Coquelle A, Pasero P, Bonnefoy N, Moreaux J, Martineau P, Del Rio M, Beijersbergen RL, Vezzio-Vie N, Gongora C.

Cancer Res. 2019 Apr 15. pii: canres.2807.2018. doi: 10.1158/0008-5472.CAN-18-2807. [Epub ahead of print]

PMID:
30987998
2.

Antioxidant Defenses Confer Resistance to High Dose Melphalan in Multiple Myeloma Cells.

Gourzones C, Bellanger C, Lamure S, Gadacha OK, De Paco EG, Vincent L, Cartron G, Klein B, Moreaux J.

Cancers (Basel). 2019 Mar 28;11(4). pii: E439. doi: 10.3390/cancers11040439.

3.

Comprehensive characterization of the mutational landscape in multiple myeloma cell lines reveals potential drivers and pathways associated with tumor progression and drug resistance.

Vikova V, Jourdan M, Robert N, Requirand G, Boireau S, Bruyer A, Vincent L, Cartron G, Klein B, Elemento O, Kassambara A, Moreaux J.

Theranostics. 2019 Jan 1;9(2):540-553. doi: 10.7150/thno.28374. eCollection 2019.

4.

Overexpression of Claspin and Timeless protects cancer cells from replication stress in a checkpoint-independent manner.

Bianco JN, Bergoglio V, Lin YL, Pillaire MJ, Schmitz AL, Gilhodes J, Lusque A, Mazières J, Lacroix-Triki M, Roumeliotis TI, Choudhary J, Moreaux J, Hoffmann JS, Tourrière H, Pasero P.

Nat Commun. 2019 Feb 22;10(1):910. doi: 10.1038/s41467-019-08886-8.

5.

EZH2 is overexpressed in transitional preplasmablasts and is involved in human plasma cell differentiation.

Herviou L, Jourdan M, Martinez AM, Cavalli G, Moreaux J.

Leukemia. 2019 Feb 12. doi: 10.1038/s41375-019-0392-1. [Epub ahead of print]

PMID:
30755708
6.

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells.

Jourdan M, de Boussac H, Viziteu E, Kassambara A, Moreaux J.

J Vis Exp. 2019 Jan 20;(143). doi: 10.3791/58929.

PMID:
30735200
7.

Myeloid-derived suppressor cells induce multiple myeloma cell survival by activating the AMPK pathway.

De Veirman K, Menu E, Maes K, De Beule N, De Smedt E, Maes A, Vlummens P, Fostier K, Kassambara A, Moreaux J, Van Ginderachter JA, De Bruyne E, Vanderkerken K, Van Valckenborgh E.

Cancer Lett. 2019 Feb 1;442:233-241. doi: 10.1016/j.canlet.2018.11.002. Epub 2018 Nov 9.

PMID:
30419344
8.

BrdU incorporation in multiparameter flow cytometry: A new cell cycle assessment approach in multiple myeloma.

Requirand G, Robert N, Boireau S, Vincent L, Seckinger A, Bouhya S, Ceballos P, Cartron G, Hose D, Klein B, Moreaux J.

Cytometry B Clin Cytom. 2018 Nov 12. doi: 10.1002/cyto.b.21730. [Epub ahead of print]

PMID:
30417559
9.

PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs.

Herviou L, Kassambara A, Boireau S, Robert N, Requirand G, Müller-Tidow C, Vincent L, Seckinger A, Goldschmidt H, Cartron G, Hose D, Cavalli G, Moreaux J.

Clin Epigenetics. 2018 Oct 3;10(1):121. doi: 10.1186/s13148-018-0554-4.

10.

Physiological and druggable skipping of immunoglobulin variable exons in plasma cells.

Ashi MO, Srour N, Lambert JM, Marchalot A, Martin O, Le Noir S, Pinaud E, Ayala MV, Sirac C, Saulière J, Moreaux J, Cogné M, Delpy L.

Cell Mol Immunol. 2018 Aug 20. doi: 10.1038/s41423-018-0160-6. [Epub ahead of print]

PMID:
30127381
11.

[EZH2 is therapeutic target for personalized treatment in multiple myeloma].

Herviou L, Cavalli G, Moreaux J.

Bull Cancer. 2018 Sep;105(9):804-819. doi: 10.1016/j.bulcan.2018.06.003. Epub 2018 Jul 2. Review. French.

PMID:
30041976
12.

Tumor-associated neutrophils correlate with poor prognosis in diffuse large B-cell lymphoma patients.

Manfroi B, Moreaux J, Righini C, Ghiringhelli F, Sturm N, Huard B.

Blood Cancer J. 2018 Jul 5;8(7):66. doi: 10.1038/s41408-018-0099-y. No abstract available.

13.

Analysis of Global Gene Expression Profiles.

Kassambara A, Moreaux J.

Methods Mol Biol. 2018;1792:157-166. doi: 10.1007/978-1-4939-7865-6_11.

PMID:
29797258
14.

An epigenetic regulator-related score (EpiScore) predicts survival in patients with diffuse large B cell lymphoma and identifies patients who may benefit from epigenetic therapy.

Szablewski V, Bret C, Kassambara A, Devin J, Cartron G, Costes-Martineau V, Moreaux J.

Oncotarget. 2018 Apr 10;9(27):19079-19099. doi: 10.18632/oncotarget.24901. eCollection 2018 Apr 10.

15.

DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells.

Bruyer A, Maes K, Herviou L, Kassambara A, Seckinger A, Cartron G, Rème T, Robert N, Requirand G, Boireau S, Müller-Tidow C, Veyrune JL, Vincent L, Bouhya S, Goldschmidt H, Vanderkerken K, Hose D, Klein B, De Bruyne E, Moreaux J.

Br J Cancer. 2018 Apr;118(8):1062-1073. doi: 10.1038/s41416-018-0025-x. Epub 2018 Mar 2.

16.

Loss of RASSF4 Expression in Multiple Myeloma Promotes RAS-Driven Malignant Progression.

De Smedt E, Maes K, Verhulst S, Lui H, Kassambara A, Maes A, Robert N, Heirman C, Cakana A, Hose D, Breckpot K, van Grunsven LA, De Veirman K, Menu E, Vanderkerken K, Moreaux J, De Bruyne E.

Cancer Res. 2018 Mar 1;78(5):1155-1168. doi: 10.1158/0008-5472.CAN-17-1544. Epub 2017 Dec 19.

17.

CD24, CD27, CD36 and CD302 gene expression for outcome prediction in patients with multiple myeloma.

Alaterre E, Raimbault S, Goldschmidt H, Bouhya S, Requirand G, Robert N, Boireau S, Seckinger A, Hose D, Klein B, Moreaux J.

Oncotarget. 2017 Oct 30;8(58):98931-98944. doi: 10.18632/oncotarget.22131. eCollection 2017 Nov 17.

18.

Extracellular S100A9 Protein in Bone Marrow Supports Multiple Myeloma Survival by Stimulating Angiogenesis and Cytokine Secretion.

De Veirman K, De Beule N, Maes K, Menu E, De Bruyne E, De Raeve H, Fostier K, Moreaux J, Kassambara A, Hose D, Heusschen R, Eriksson H, Vanderkerken K, Van Valckenborgh E.

Cancer Immunol Res. 2017 Oct;5(10):839-846. doi: 10.1158/2326-6066.CIR-17-0192. Epub 2017 Sep 13.

19.

Automated and simplified identification of normal and abnormal plasma cells in Multiple Myeloma by flow cytometry.

Alaterre E, Raimbault S, Garcia JM, Rème T, Requirand G, Klein B, Moreaux J.

Cytometry B Clin Cytom. 2018 May;94(3):484-492. doi: 10.1002/cyto.b.21590. Epub 2017 Sep 19.

PMID:
28865180
20.

Characterization of human FCRL4-positive B cells.

Jourdan M, Robert N, Cren M, Thibaut C, Duperray C, Kassambara A, Cogné M, Tarte K, Klein B, Moreaux J.

PLoS One. 2017 Jun 21;12(6):e0179793. doi: 10.1371/journal.pone.0179793. eCollection 2017.

21.

Hypoxia favors the generation of human plasma cells.

Schoenhals M, Jourdan M, Bruyer A, Kassambara A, Klein B, Moreaux J.

Cell Cycle. 2017 Jun 3;16(11):1104-1117. doi: 10.1080/15384101.2017.1317408. Epub 2017 May 2.

22.

Global miRNA expression analysis identifies novel key regulators of plasma cell differentiation and malignant plasma cell.

Kassambara A, Jourdan M, Bruyer A, Robert N, Pantesco V, Elemento O, Klein B, Moreaux J.

Nucleic Acids Res. 2017 Jun 2;45(10):5639-5652. doi: 10.1093/nar/gkx327.

23.

RECQ1 helicase is involved in replication stress survival and drug resistance in multiple myeloma.

Viziteu E, Klein B, Basbous J, Lin YL, Hirtz C, Gourzones C, Tiers L, Bruyer A, Vincent L, Grandmougin C, Seckinger A, Goldschmidt H, Constantinou A, Pasero P, Hose D, Moreaux J.

Leukemia. 2017 Oct;31(10):2104-2113. doi: 10.1038/leu.2017.54. Epub 2017 Feb 10.

24.

Forced KLF4 expression increases the generation of mature plasma cells and uncovers a network linked with plasma cell stage.

Schoenhals M, Jourdan M, Seckinger A, Pantesco V, Hose D, Kassambara A, Moreaux J, Klein B.

Cell Cycle. 2016 Jul 17;15(14):1919-28. doi: 10.1080/15384101.2016.1191709. Epub 2016 May 26.

25.

Differential effects of lenalidomide during plasma cell differentiation.

Jourdan M, Cren M, Schafer P, Robert N, Duperray C, Vincent L, Ceballos P, Cartron G, Rossi JF, Moreaux J, Chopra R, Klein B.

Oncotarget. 2016 May 10;7(19):28096-111. doi: 10.18632/oncotarget.8581.

26.

[Does consumption of tobacco, alcohol, and cannabis in adolescents and young adults with cancer affect the use of analgesics during hospitalizations?].

Bertrand A, Boyle H, Moreaux J, Guillot L, Chvetzoff G, Charbonnel JF, Marec-Berard P.

Arch Pediatr. 2016 Apr;23(4):353-9. doi: 10.1016/j.arcped.2015.12.022. Epub 2016 Mar 8. French.

PMID:
26968307
27.

RECQ helicases are deregulated in hematological malignancies in association with a prognostic value.

Viziteu E, Kassambara A, Pasero P, Klein B, Moreaux J.

Biomark Res. 2016 Feb 13;4:3. doi: 10.1186/s40364-016-0057-4. eCollection 2016.

28.

Chetomin, targeting HIF-1α/p300 complex, exhibits antitumour activity in multiple myeloma.

Viziteu E, Grandmougin C, Goldschmidt H, Seckinger A, Hose D, Klein B, Moreaux J.

Br J Cancer. 2016 Mar 1;114(5):519-23. doi: 10.1038/bjc.2016.20. Epub 2016 Feb 11.

29.

Identifying high-risk adult AML patients: epigenetic and genetic risk factors and their implications for therapy.

Bret C, Viziteu E, Kassambara A, Moreaux J.

Expert Rev Hematol. 2016;9(4):351-60. doi: 10.1586/17474086.2016.1141673. Epub 2016 Feb 12. Review.

PMID:
26761438
30.

Inhibiting the anaphase promoting complex/cyclosome induces a metaphase arrest and cell death in multiple myeloma cells.

Lub S, Maes A, Maes K, De Veirman K, De Bruyne E, Menu E, Fostier K, Kassambara A, Moreaux J, Hose D, Leleu X, King RW, Vanderkerken K, Van Valckenborgh E.

Oncotarget. 2016 Jan 26;7(4):4062-76. doi: 10.18632/oncotarget.6768.

31.

EZH2 in normal hematopoiesis and hematological malignancies.

Herviou L, Cavalli G, Cartron G, Klein B, Moreaux J.

Oncotarget. 2016 Jan 19;7(3):2284-96. doi: 10.18632/oncotarget.6198. Review.

32.

miRNAs in multiple myeloma--a survival relevant complex regulator of gene expression.

Seckinger A, Meißner T, Moreaux J, Benes V, Hillengass J, Castoldi M, Zimmermann J, Ho AD, Jauch A, Goldschmidt H, Klein B, Hose D.

Oncotarget. 2015 Nov 17;6(36):39165-83. doi: 10.18632/oncotarget.5381.

33.

Factors influencing extramedullary relapse after allogeneic transplantation for multiple myeloma.

Vincent L, Ceballos P, Plassot C, Méniane JC, Quittet P, Navarro R, Cyteval C, Szablewski V, Lu ZY, Kanouni T, Moreaux J, Cartron G, Klein B, Fegueux N.

Blood Cancer J. 2015 Aug 21;5:e341. doi: 10.1038/bcj.2015.48. No abstract available.

34.

SNaPshot as a Valuable Option for the Identification of Mutations in Myeloma.

Moreaux J.

EBioMedicine. 2014 Nov 20;2(1):13-4. doi: 10.1016/j.ebiom.2014.11.014. eCollection 2015 Jan. No abstract available.

35.

Expression and role of RIP140/NRIP1 in chronic lymphocytic leukemia.

Lapierre M, Castet-Nicolas A, Gitenay D, Jalaguier S, Teyssier C, Bret C, Cartron G, Moreaux J, Cavaillès V.

J Hematol Oncol. 2015 Mar 4;8:20. doi: 10.1186/s13045-015-0116-6. Review.

36.

Drug metabolism and clearance system in tumor cells of patients with multiple myeloma.

Hassen W, Kassambara A, Reme T, Sahota S, Seckinger A, Vincent L, Cartron G, Moreaux J, Hose D, Klein B.

Oncotarget. 2015 Mar 20;6(8):6431-47.

37.

In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma.

Maes K, De Smedt E, Kassambara A, Hose D, Seckinger A, Van Valckenborgh E, Menu E, Klein B, Vanderkerken K, Moreaux J, De Bruyne E.

Oncotarget. 2015 Feb 20;6(5):3319-34.

38.

The 7p15.3 (rs4487645) association for multiple myeloma shows strong allele-specific regulation of the MYC-interacting gene CDCA7L in malignant plasma cells.

Weinhold N, Meissner T, Johnson DC, Seckinger A, Moreaux J, Försti A, Chen B, Nickel J, Chubb D, Rawstron AC, Doughty C, Dahir NB, Begum DB, Young K, Walker BA, Hoffmann P, Nöthen MM, Davies FE, Klein B, Goldschmidt H, Morgan GJ, Houlston RS, Hose D, Hemminki K.

Haematologica. 2015 Mar;100(3):e110-3. doi: 10.3324/haematol.2014.118786. Epub 2014 Dec 5. No abstract available.

39.

DNA repair in diffuse large B-cell lymphoma: a molecular portrait.

Bret C, Klein B, Cartron G, Schved JF, Constantinou A, Pasero P, Moreaux J.

Br J Haematol. 2015 Apr;169(2):296-9. doi: 10.1111/bjh.13206. Epub 2014 Nov 5. No abstract available.

PMID:
25369781
40.

Identification of a 20-gene expression-based risk score as a predictor of clinical outcome in chronic lymphocytic leukemia patients.

Bou Samra E, Klein B, Commes T, Moreaux J.

Biomed Res Int. 2014;2014:423174. doi: 10.1155/2014/423174. Epub 2014 May 5.

41.

A DNA repair pathway score predicts survival in human multiple myeloma: the potential for therapeutic strategy.

Kassambara A, Gourzones-Dmitriev C, Sahota S, Rème T, Moreaux J, Goldschmidt H, Constantinou A, Pasero P, Hose D, Klein B.

Oncotarget. 2014 May 15;5(9):2487-98.

42.

Identification and characterization of new Leishmania promastigote surface antigens, LaPSA-38S and LiPSA-50S, as major immunodominant excreted/secreted components of L. amazonensis and L. infantum.

Bras-Gonçalves R, Petitdidier E, Pagniez J, Veyrier R, Cibrelus P, Cavaleyra M, Maquaire S, Moreaux J, Lemesre JL.

Infect Genet Evol. 2014 Jun;24:1-14. doi: 10.1016/j.meegid.2014.02.017. Epub 2014 Mar 7.

PMID:
24614507
43.

The glycome of normal and malignant plasma cells.

Moehler TM, Seckinger A, Hose D, Andrulis M, Moreaux J, Hielscher T, Willhauck-Fleckenstein M, Merling A, Bertsch U, Jauch A, Goldschmidt H, Klein B, Schwartz-Albiez R.

PLoS One. 2013 Dec 26;8(12):e83719. doi: 10.1371/journal.pone.0083719. eCollection 2013.

44.

DNA methylation score is predictive of myeloma cell sensitivity to 5-azacitidine.

Moreaux J, Bruyer A, Veyrune JL, Goldschmidt H, Hose D, Klein B.

Br J Haematol. 2014 Feb;164(4):613-6. doi: 10.1111/bjh.12660. Epub 2013 Nov 13. No abstract available.

45.

DNA repair pathways in human multiple myeloma: role in oncogenesis and potential targets for treatment.

Gourzones-Dmitriev C, Kassambara A, Sahota S, Rème T, Moreaux J, Bourquard P, Hose D, Pasero P, Constantinou A, Klein B.

Cell Cycle. 2013 Sep 1;12(17):2760-73. doi: 10.4161/cc.25951. Epub 2013 Aug 9. Review.

46.

Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors.

Moreaux J, Reme T, Leonard W, Veyrune JL, Requirand G, Goldschmidt H, Hose D, Klein B.

Br J Cancer. 2013 Aug 6;109(3):676-85. doi: 10.1038/bjc.2013.392. Epub 2013 Jul 18.

47.

Nucleotide excision DNA repair pathway as a therapeutic target in patients with high-risk diffuse large B cell lymphoma.

Bret C, Klein B, Moreaux J.

Cell Cycle. 2013 Jun 15;12(12):1811-2. doi: 10.4161/cc.25115. Epub 2013 May 24. No abstract available.

48.

Inhibition of DEPDC1A, a bad prognostic marker in multiple myeloma, delays growth and induces mature plasma cell markers in malignant plasma cells.

Kassambara A, Schoenhals M, Moreaux J, Veyrune JL, Rème T, Goldschmidt H, Hose D, Klein B.

PLoS One. 2013 Apr 30;8(4):e62752. doi: 10.1371/journal.pone.0062752. Print 2013.

49.

Krüppel-like factor 4 blocks tumor cell proliferation and promotes drug resistance in multiple myeloma.

Schoenhals M, Kassambara A, Veyrune JL, Moreaux J, Goldschmidt H, Hose D, Klein B.

Haematologica. 2013 Sep;98(9):1442-9. doi: 10.3324/haematol.2012.066944. Epub 2013 Apr 12.

50.

Gene expression-based risk score in diffuse large B-cell lymphoma.

Bret C, Klein B, Moreaux J.

Oncotarget. 2012 Dec;3(12):1700-10.

Supplemental Content

Loading ...
Support Center